Delaware Chapter of the American College of CardiologyOur purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments. |
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Is Occupational Physical Work Exposure a Risk Factor For ATTRwt-CM?In a registry-based study, an association was found between transthyretin wild-type amyloid cardiomyopathy (ATTRwt-CM) and occupational upper-body mechanical stress, along with a greater burden of orthopedic and cardiovascular comorbidities including increased cardiovascular mortality among patients with ATTRwt-CM. The hypothesis-generating findings were published Feb. 24 in JACC: Advances.
- Is Progression of Myocardial Fibrosis a Risk Indicator in HCM?Myocardial fibrosis increased over time in patients with hypertrophic cardiomyopathy (HCM), as assessed by late gadolinium enhancement (LGE) on follow-up cardiac MR, suggesting a higher risk for adverse outcomes, including all-cause mortality, hospitalization and stroke, according to research published Feb. 20 in JACC: Cardiovascular Imaging.
- Nonobstructive HCM Treatment: Differential Effect of Bisoprolol vs. VerapamilBisoprolol but not verapamil reduced peak oxygen consumption (pVO2) in patients with nonobstructive hypertrophic cardiomyopathy (HCM), according to research published March 3 in JACC.
- Your ACC Urges Reclassification of APRN, PA Degrees as ProfessionalThe U.S. Department of Education has categorized APRN and PA clinicians as "graduate" students rather than "professional" students under the One Big Beautiful Bill Act, lowering their federal loan limits.
- Extended DAPT in Multivessel CAD: Less Ischemia Without a Major Bleeding PenaltyThe DAPT-MVD (Dual Antiplatelet Therapy in Patients With Coronary Multi-Vessel Disease) trial was a multicenter, randomized, open-label study in China designed to assess whether extending dual antiplatelet therapy (DAPT) beyond 12 months provides additional benefit for patients with multivessel coronary artery disease (CAD)...



